{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:49:07Z","timestamp":1791920947672,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bmcl.2021.128168","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:09:08Z","timestamp":1622833748000},"page":"128168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation"],"prefix":"10.1016","volume":"47","author":[{"given":"Wensheng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christine Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.O.","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2021.128168_b0005","unstructured":"Source : https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed at February 19th, 2021."},{"key":"10.1016\/j.bmcl.2021.128168_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/clpt.2012.202","article-title":"Prospects for treatment of latent HIV","volume":"93","author":"Barton","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2021.128168_b0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/infdis\/jiv218","article-title":"Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies","volume":"212","author":"Crooks","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bmcl.2021.128168_b0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"issue":"7408","key":"10.1016\/j.bmcl.2021.128168_b0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"Shock and Kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128168_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","article-title":"HIV latency: should we shock or lock","volume":"38","author":"Darcis","year":"2017","journal-title":"Trends Immunol"},{"issue":"6649","key":"10.1016\/j.bmcl.2021.128168_b0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128168_b0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0092-8674(00)80211-1","article-title":"What's up and down with histone deacetylation and transcription?","volume":"89","author":"Pazin","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2021.128168_b0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2021.128168_b0050","first-page":"35","article-title":"Clinical use and applications of histone deacetylase inhibitors in multiple myeloma","volume":"8","author":"Tandon","year":"2016","journal-title":"Clin Pharmacol: Adv Appl"},{"key":"10.1016\/j.bmcl.2021.128168_b0055","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128168_b0060","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV."},{"issue":"9","key":"10.1016\/j.bmcl.2021.128168_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2021.128168_b0070","doi-asserted-by":"crossref","unstructured":"S. Leth H.M. Schleimann K.S. Nissen et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial Lancet HIV S2352\u20133018 16 2016 30055 8.","DOI":"10.1016\/S2352-3018(16)30055-8"},{"key":"10.1016\/j.bmcl.2021.128168_b0075","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2021.128168_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-6527-4_3","article-title":"Assessment of HDACi-induced cytotoxicity","volume":"1510","author":"Marx-Bl\u00fcmel","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"23","key":"10.1016\/j.bmcl.2021.128168_b0085","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1016\/j.bmcl.2008.10.052","article-title":"SAR profiles of spirocyclic nicotinamide derived selective HDAC1\/HDAC2 inhibitors (SHI-1:2)","volume":"18","author":"Methot","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128168_b0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/ml4004233","article-title":"Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1\/HDAC2 Inhibitor","volume":"5","author":"Methot","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128168_b0095","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1128\/JVI.01383-08","article-title":"Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency","volume":"82","author":"Pearson","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2021.128168_b0100","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1128\/JVI.01519-09","article-title":"Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction","volume":"84","author":"Tyagi","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2021.128168_b0105","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1128\/JVI.00836-11","article-title":"Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2","volume":"85","author":"Friedman","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2021.128168_b0110","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1073\/pnas.93.23.13143","article-title":"Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase","volume":"93","author":"Darkin-Rattray","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2021.128168_b0115","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1021\/jm9004303","article-title":"Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties","volume":"52","author":"Kinzel","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128168_b0120","doi-asserted-by":"crossref","first-page":"127197","DOI":"10.1016\/j.bmcl.2020.127197","article-title":"Discovery of ethyl ketone-based HDAC-1,2,3 selective inhibitors for HIV latency reactivation","volume":"30","author":"Yu","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128168_b0125","unstructured":"All compounds tested in this publication had purity > 95% determined by LCMS or HPLC, and their structures were fully characterized by LCMS and 1H-NMR spectra. All reported values were the mean of two assay measurements or greater. Standard deviation was within three-fold of the reported value for all compounds. For HDAC enzymatic and 2C4 cell-based HIV reactivation assay methods, see reference 27."},{"key":"10.1016\/j.bmcl.2021.128168_b0130","doi-asserted-by":"crossref","first-page":"127367","DOI":"10.1016\/j.bmcl.2020.127367","article-title":"Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir","volume":"30","author":"Clausen","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128168_b0135","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.jmedchem.0c02150","article-title":"Discovery of ethyl ketone-based highly selective HDACs 1, 2, 3 inhibitors for HIV latency reactivation with minimum cellular potency serum shift and reduced hERG activity","volume":"64","author":"Yu","year":"2021","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21003954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21003954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:41:32Z","timestamp":1760773292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21003954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"alternative-id":["S0960894X21003954"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128168","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128168"}}